Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PsychoGenics Inc.

Latest From Prolysis Ltd.

Wellcome Trust extends funding initiative for early stage drug discovery

The Wellcome Trust will continue to help fund the early stages of drug discovery for another five years by extending its Seeding Drug Discovery initiative with a further £110 million.

Biota acquires antibacterial projects from two firms

Biota Holdings has acquired early stage antibacterial programmes from the UK firm Prolysis and MaxThera of the US, in an effort to extend its research interests beyond antivirals and into the wider anti-infective area.

Infectious Diseases Respiratory

Start-Up Previews (11/04)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Biotechs Battle Bacteria, features profiles of AureoGen Biosciences, Biovertis, Inimex Pharmaceuticals and Prolysis. Plus these Start-Ups across Health Care: Afmedica, Intercept Pharmaceuticals and MAP Pharmaceuticals.

Prolysis Ltd.

Prolysis Ltd. reckons it has a head start over other biotechs seeking novel anti-infectives because its core technology--a series of whole cell assays targeting critical bacterial pathways--allows it to select, early on, only those compounds that get inside the bacterial cell.
BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Transgenics
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • PGI Drug Discovery LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • PsychoGenics Inc.
  • Senior Management
  • Emer Leahy, PhD, Pres. & CEO
    William C Fasnacht, CFO & COO
    Bavani Shankar, VP, Corp. Dev.
    David A Lowe, PhD, EVP, R&D & CSO
  • Contact Info
  • PsychoGenics Inc.
    Phone: (914) 406-8019
    765 Old Saw Mill River Rd.
    Tarrytown, NY 10591